HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA promotes OTC safety

This article was originally published in The Tan Sheet

Executive Summary

United Health Foundation is teaming with FDA on a national health education campaign designed to promote safe use of OTCs. Targeted to women ages 25-60, print ads include a Q&A reminding OTC users to read and follow directions, avoid taking products with the same active ingredient and consult healthcare professionals in the event of side effects. The ads will appear in magazines such as People, Good Housekeeping and Ebony, as well as online news sources Yahoo!, AOL and ABCNews.com. The campaign echoes an OTC safety initiative launched by the agency last year (1"The Tan Sheet" Jan. 26, 2004, p. 8)...

You may also be interested in...



FDA Analgesic Safety Campaign Launches; Label Warnings Still In Progress

FDA launched a public educational campaign Jan. 22 warning consumers about the link between acetaminophen and liver damage, and potential renal and gastrointestinal problems associated with nonsteroidal anti-inflammatory use

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS127118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel